Nutra Pharma Corp. Announces Interviews With Wall Street Buy Sell Hold
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is the CEO's first in almost two years and outlines the short, mid-term and long-term goals of the company. Castaldo also interviewed Jonathan Flicker, the CEO of Nutra Pharma's new Nyloxin™ Distributor, New Vitality.
Help employers find you! Check out all the jobs and post your resume.
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that their Chief Executive Officer, Rik Deitsch, was interviewed by Chris Castaldo of Wall Street Buy Sell Hold. The interview is the CEO's first in almost two years and outlines the short, mid-term and long-term goals of the company. Castaldo also interviewed Jonathan Flicker, the CEO of Nutra Pharma's new Nyloxin™ Distributor, New Vitality.
Help employers find you! Check out all the jobs and post your resume.